Scouting for GI disease assets for in-licensing

Challenge: A disease area unit within a global biopharmaceutical company was charged with a mandate to seek out novel candidate assets in development to treat inflammatory bowel disease (IBD) and...
Learn More

Benchmarking deal terms & formulating negotiating positions for AI discovery company

Project Challenge: Our client was a company on which we had conducted due diligence for an investor approached us for support with a potential deal with an AI discovery company. The concept was to...
Learn More

Scouting for metabolic disease assets to license

Challenge: A venture capital portfolio company developing small molecule therapeutics for metabolic/obesity indications had made the strategic decision to supplement their internal product pipeline...
Learn More

Assessing the clinical development & regulatory pathway for a Phase 3 gene therapy product

Challenge Our client, a PE-backed specialty pharma company growing rapidly through M&A, was assessing a number of late-stage development projects to license/acquire. The company was considering a...
Learn More

Clinical due diligence on a company targeting CNS indications

Challenge A major VC fund asked Alacrita to conduct a clinical due diligence on a potential investment in a company targeting CNS indications. The target company was led by an executive with whom the...
Learn More

Valuation of a radiolabeled peptide for diagnosis of pulmonary diseases

Challenge: In preparation for fundraising, a biotech company developing a clinical stage radiolabeled peptide to diagnose pulmonary diseases required an independent valuation of its technology in...
Learn More

KOL & payer market research for small molecule in aortic valve stenosis

Challenge A European investor required due diligence on a lead preclinical candidate being developed by a biotech company for the treatment and prevention of aortic valve stenosis (AVS). Alacrita was...
Learn More

Providing due diligence in inflammation and fibrosis area

Challenge: An innovation fund interested in a research institute developing proprietary mAbs against a novel liver disease target, asked Alacrita to conduct due diligence on the development of this...
Learn More

Scouting for Assets in CNS

Challenge: An early-stage biotechnology company with several assets in pre-clinical development for CNS diseases wanted to supplement its internal pipeline with external innovation. The company...
Learn More

Provision of support for creating an investor prospectus

Challenge: A biotech company focusing in fibrosis and autoimmunity was planning a reverse takeover transaction with a listed entity and required support in formulating its proxy statement (investor...
Learn More

Investor due diligence for a live biotherapeutic product

Challenge: A developer of live biotherapeutic products (LBP) derived from stool donations had a lead product in phase 2 clinical trials for metabolic pathology secondary to hepatic pathology. An...
Learn More

Due diligence on a computational chemistry software for a private equity firm

Challenge: A generalist private equity firm was considering an investment in a computational chemistry company, and required an evaluation of the company’s software suite as part of its due diligence...
Learn More